Double-Blind, Placebo-Controlled, 20-Week, Parallel Group Study to Evaluate Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2011
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Sponsors Acorda Therapeutics
- 11 Apr 2011 Efficacy and adverse events data presented at the 63rd Annual Meeting of the American Academy of Neurology (AAN-2011), according to an Acorda Therapeutics media release.
- 16 Nov 2010 Checked against NCT record.
- 05 Nov 2010 New trial record.